Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
15 May 2024
Historique:
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

Trichophyton indotineae is an emerging dermatophyte causing outbreaks of extensive tinea infections often unresponsive to terbinafine. This species has been detected worldwide and in multiple US states, yet detailed US data on infections with T indotineae are sparse and could improve treatment practices and medical understanding of transmission. To correlate clinical features of T indotineae infections with in vitro antifungal susceptibility testing results, squalene epoxidase gene sequence variations, and isolate relatedness using whole-genome sequencing. This retrospective cohort study of patients with T indotineae infections in New York City spanned May 2022 to May 2023. Patients with confirmed T indotineae infections were recruited from 6 New York City medical centers. Improvement or resolution at the last follow-up assessment. Among 11 patients with T indotineae (6 male and 5 female patients; median [range] age, 39 [10-65] years), 2 were pregnant; 1 had lymphoma; and the remainder were immunocompetent. Nine patients reported previous travel to Bangladesh. All had widespread lesions with variable scale and inflammation, topical antifungal monotherapy failure, and diagnostic delays (range, 3-42 months). Terbinafine treatment failed in 7 patients at standard doses (250 mg daily) for prolonged duration; these patients also had isolates with amino acid substitutions at positions 393 (L393S) or 397 (F397L) in squalene epoxidase that correlated with elevated terbinafine minimum inhibitory concentrations of 0.5 μg/mL or higher. Patients who were treated with fluconazole and griseofulvin improved in 2 of 4 and 2 of 5 instances, respectively, without correlation between outcomes and antifungal minimum inhibitory concentrations. Furthermore, 5 of 7 patients treated with itraconazole cleared or had improvement at the last follow-up, and 2 of 7 were lost to follow-up or stopped treatment. Based on whole-genome sequencing analysis, US isolates formed a cluster distinct from Indian isolates. The results of this case series suggest that disease severity, diagnostic delays, and lack of response to typically used doses and durations of antifungals for tinea were common in this primarily immunocompetent patient cohort with T indotineae, consistent with published data. Itraconazole was generally effective, and the acquisition of infection was likely in Bangladesh.

Identifiants

pubmed: 38748419
pii: 2818522
doi: 10.1001/jamadermatol.2024.1126
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Avrom S Caplan (AS)

The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
Dermatology Service, Bellevue Hospital Center, New York, New York.

Gabrielle C Todd (GC)

Wadsworth Center Mycology Laboratory, New York State Department of Health, Albany.

YanChun Zhu (Y)

Wadsworth Center Mycology Laboratory, New York State Department of Health, Albany.

Michelle Sikora (M)

The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.

Christine C Akoh (CC)

The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
Dermatology Service, Bellevue Hospital Center, New York, New York.

Jeannette Jakus (J)

SUNY Downstate Health Sciences University, Department of Dermatology, Brooklyn, New York.

Shari R Lipner (SR)

Department of Dermatology, Weill Cornell Medicine, New York, New York.

Kayla Babbush (K)

Department of Dermatology, Weill Cornell Medicine, New York, New York.

Karen P Acker (KP)

Division of Infectious Diseases, Department of Pediatrics, Weill Cornell Medicine, New York, New York.

Ayana E Morales (AE)

Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York.

Rebecca M Marrero Rolón (RMM)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

Lars F Westblade (LF)

Division of Infectious Diseases, Department of Pediatrics, Weill Cornell Medicine, New York, New York.
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

Maira Fonseca (M)

Department of Dermatology, Weill Cornell Medicine, New York, New York.
NYC Health + Hospitals/Lincoln Medical Center, Department of Dermatology, Bronx, New York, USA Department of Dermatology, Weill Cornell Medicine, New York.

Abigail Cline (A)

Department of Dermatology, Weill Cornell Medicine, New York, New York.
NYC Health + Hospitals/Lincoln Medical Center, Department of Dermatology, Bronx, New York, USA Department of Dermatology, Weill Cornell Medicine, New York.

Jeremy A W Gold (JAW)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.

Shawn R Lockhart (SR)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.

Dallas J Smith (DJ)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.

Tom Chiller (T)

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.

William G Greendyke (WG)

New York City Department of Health and Mental Hygiene, New York, New York.

Swati R Manjari (SR)

Division of Translational Medicine, Wadsworth Center, New York State Department of Health, Albany.

Nilesh K Banavali (NK)

Division of Translational Medicine, Wadsworth Center, New York State Department of Health, Albany.
Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York.

Sudha Chaturvedi (S)

Wadsworth Center Mycology Laboratory, New York State Department of Health, Albany.
Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York.

Classifications MeSH